In the future, we expect obesity care to become much more differentiated, and with BI 3034701, we aim to go beyond short-term weight loss and address both the biological and behavioral drivers of obesity. BI 3034701 is part of a broader portfolio of therapies being developed for people living with obesity or obesity and connected metabolic health conditions, which has multiple approaches under investigation, including survodutide, a dual glucagon/GLP-1 agonist
Injectable GHK-Cu has more systemic exposure but still doesnt interact with GLP-1 receptor biology
If you inject 1 mg of semaglutide on Monday, by the following Monday about 0.5 mg remains in your system
To extend stability, peptide solutions are often stored in sterile buffers with a pH around 56 and kept at -20C or colder when appropriate
You can utilize strength training to counteract the negative impacts on your muscular compositionand, in turn, that strength work will support stronger, more powerful cycling, too